We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Feedback Plc | LSE:FDBK | London | Ordinary Share | GB00BJN59X09 | ORD 50P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-2.50 | -2.38% | 102.50 | 100.00 | 105.00 | 105.00 | 102.50 | 105.00 | 13,665 | 10:19:31 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Electronic Computers | 1.03M | -2.92M | -0.2188 | -4.68 | 13.67M |
TIDMFDBK
RNS Number : 9478K
Feedback PLC
16 April 2018
This announcement contains inside information as stipulated under the Market Abuse Regulation (EU) No 596/2014 (MAR).
16 April 2018
Feedback plc
(the "Company" or "Feedback")
New company structure and changes to the Board of Directors
Cambridge, UK - 16 April 2018: Feedback plc ("Feedback" or the "Company") (AIM: FDBK), the specialist medical imaging technology company, announces a new company structure and changes to the Board of Directors to optimise Feedback's operations and continue to build the Company's presence in the field of medical imaging.
New company structure
Feedback acquired Cambridge Computed Imaging Ltd ("CCI") and TexRAD Limited in 2014, and both companies have been operating as wholly-owned subsidiaries since. As part of a strategic review to streamline operations and act as a fully-integrated organisation, CCI has been renamed to Feedback Medical Limited and TexRAD Limited will become dormant. All employees will be working for Feedback Medical Limited as a wholly-owned subsidiary of Feedback. These organisational changes are aligned to the Company's mission to create evidence-based imaging software, arming clinicians with innovative tools to improve patient outcomes.
Changes to the Board of Directors
As part of the organisational changes, Mike Hayball and Dr Balaji Ganeshan have resigned as Executive Directors of Feedback plc with immediate effect. Mike Hayball will continue as Director of Feedback Medical Limited and Dr Balaji Ganeshan has been appointed as a Director of Feedback Medical Limited. In addition, Dr Alex Menys has stepped down as Non-Executive Director with immediate effect having served on the Board since November 2015. Simon Sturge has been appointed as Non-Executive Director with immediate effect (see separate announcement). Furthermore, Dr Alastair Riddell and Simon Sturge will receive share options in lieu of fees to reduce board cash costs and a further announcement will be made when such options are granted.
Dr Alastair Riddell, Chairman of Feedback, said: "These changes represent an important step for Feedback to simplify its organisation and continue to leverage its global brand in the field of medical imaging. On behalf of the Board I would like to thank Dr Alex Menys for his support since 2015 as Feedback's progress has evolved. In streamlining the Board, we now have complementary expertise across the Non-Executive and Executive Directors and are well-positioned to support the Company's growth strategy."
David Crabb, Chief Executive Officer of Feedback, said: "Over the past two months I have been focused on unlocking the significant potential in optimising and expanding Feedback's operations. I believe that these organisational changes will unify the team, improve business performance and raise awareness of the Company globally. With two, well-established platform technologies and deep domain expertise, I look forward to delivering continued progress towards our long-term vision to lead global innovation in quantitative medical imaging analysis."
-- Ends --
Notes to editors
About Feedback plc
Feedback plc is a specialist medical imaging technology company. It develops software and systems that provide innovative techniques and improved workflows for practitioners involved in medical research and treating patients. TexRAD(R) , the Company's patented quantitative image texture analysis technology, has the potential to assist clinicians in diagnosis, prognosis and treatment of patients with cancer and is currently installed in over 40 of the world's leading research institutions across Europe, North America, Asia and Australasia. The Cadran platform provides a suite of medical imaging tools for decision support. The Cadran range includes the picture archiving communication system (PACS) to provide decision support for scan analysis, diagnostic workstations which provide secure remote access to view scans on demand, and products to securely share and transport patient data. Visit www.fbk.com.
For further information, please contact:
Feedback plc Tel: 01954 718072 David Crabb, Chief Executive Officer IR@fbk.com Lara Mott, Investor Relations Allenby Capital Limited (Nominated Adviser and Tel: 020 3328 5656 Joint Broker) David Worlidge / Asha Chotai Northland Capital Partners Ltd (Joint Broker) Tel: 020 3861 6625 David Hignell / John Howes Peterhouse Corporate Finance Ltd (Joint Broker) Tel: 020 7469 093 Lucy Williams / Duncan Vasey
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCBCGDSLSBBGIU
(END) Dow Jones Newswires
April 16, 2018 02:30 ET (06:30 GMT)
1 Year Feedback Chart |
1 Month Feedback Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions